Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  CNS and Neurological Disorders - Drug Targets

• Publication date

  2016-09-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1871527315666160720120326PMID 27450870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.

  2016cited by this paper
• Mesial temporal lobe epilepsy with psychiatric comorbidities: a place for differential neuroinflammatory interplay

  2015cited by this paper
• The Effects of Sodium Nitroprusside Treatment on Cognitive Deficits in Schizophrenia: A Pilot Study

  2015cited by this paper
• Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

  2015cited by this paper
• Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week.

  2015cited by this paper
• Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia

  2015cited by this paper
• Methylene Blue Modulates β-Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice*

  2014cited by this paper
• Neurotrophin receptors expression in mesial temporal lobe epilepsy with and without psychiatric comorbidities and their relation with seizure type and surgical outcome

  2014cited by this paper
• Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems.

  2014cited by this paper
• The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.

  2014cited by this paper
• Sodium nitroprusside treatment of clozapine-refractory schizophrenia.

  2014cited by this paper
• Tau-aggregation inhibitor therapy for Alzheimer's disease.

  2014cited by this paper
• Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

  2014cited by this paper
• Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.

  2014cited by this paper
• Nitric oxide and symptom reduction in schizophrenia.

  2013cited by this paper
• Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.

  2013cited by this paper
• Discovering new treatments for Alzheimer's disease by repurposing approved medications.

  2013cited by this paper
• Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies.

  2013cited by this paper
• Therapeutic strategies in Friedreich's ataxia.

  2013cited by this paper
• Neurotrophins in mesial temporal lobe epilepsy with and without psychiatric comorbidities.

  2013cited by this paper
• Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

  2012cited by this paper
• A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists

  2012cited by this paper
• Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models.

  2012cited by this paper
• Soluble forms of tau are toxic in Alzheimer’s disease

  2012cited by this paper
• Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

  2012cited by this paper
• Biochemistry and cell biology of tau protein in neurofibrillary degeneration.

  2012cited by this paper
• Methylene Blue Modulates Huntingtin Aggregation Intermediates and Is Protective in Huntington's Disease Models

  2012cited by this paper
• Central nervous tissue damage after hypoxia and reperfusion in conjunction with cardiac arrest and cardiopulmonary resuscitation: mechanisms of action and possibilities for mitigation.

  2012cited by this paper
• Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis.

  2012cited by this paper
• Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice

  2012cited by this paper
• Pathophysiology of mood disorders in temporal lobe epilepsy.

  2012cited by this paper
• Neurotrophins induce nitric oxide generation in human pulmonary artery endothelial cells.

  2011cited by this paper
• "Lest we forget you--methylene blue...".

  2011cited by this paper
• Cellular and molecular actions of Methylene Blue in the nervous system

  2011cited by this paper
• Methylene Blue Reduces Aβ Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity

  2011cited by this paper
• Alternative Mitochondrial Electron Transfer as a Novel Strategy for Neuroprotection*

  2011cited by this paper
• Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia.

  2011cited by this paper
• Beneficial network effects of methylene blue in an amnestic model

  2011cited by this paper
• Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues.

  2010cited by this paper
• Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase

  2010cited by this paper
• A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock.

  2010cited by this paper
• Methylene blue protects the cortical blood–brain barrier against ischemia/reperfusion-induced disruptions*

  2010cited by this paper
• Phosphorylated and cleaved TDP‐43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP‐43 proteinopathy

  2010cited by this paper
• Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment

  2009cited by this paper
• An update on treatment and prevention strategies for Alzheimer’s disease

  2009cited by this paper
• Strong Gametocytocidal Effect of Methylene Blue-Based Combination Therapy against Falciparum Malaria: A Randomised Controlled Trial

  2009cited by this paper
• Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy

  2009cited by this paper
• Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties.

  2009cited by this paper
• Methylene blue and dimebon inhibit aggregation of TDP‐43 in cellular models

  2009cited by this paper
• High absolute bioavailability of methylene blue given as an aqueous oral formulation

  2009cited by this paper
• Methylene Blue Dye—A Safe and Effective Alternative for Sentinel Lymph Node Localization

  2008cited by this paper
• Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain.

  2008cited by this paper
• The molecular neurobiology of depression

  2008cited by this paper
• Therapeutic Strategies for Alzheimer’s Disease

  2008cited by this paper
• Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine

  2008cited by this paper
• Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction

  2007cited by this paper
• Interactions of Methylene Blue with Human Disulfide Reductases and Their Orthologues from Plasmodium falciparum

  2007cited by this paper
• Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

  2007cited by this paper
• Cardio-cerebral and metabolic effects of methylene blue in hypertonic sodium lactate during experimental cardiopulmonary resuscitation.

  2007cited by this paper
• Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization.

  2007cited by this paper
• Neuro‐ and Cardioprotective Effects of Blockade of Nitric Oxide Action by Administration of Methylene Blue

  2007cited by this paper
• Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

  2006cited by this paper
• Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease

  2006cited by this paper
• Inhibition of choline oxidase by quinoid dyes

  2006cited by this paper
• Methylene blue implicated in potentially fatal serotonin toxicity

  2006cited by this paper
• The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease

  2006cited by this paper
• Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects

  2006cited by this paper
• Tau, tangles, and Alzheimer's disease.

  2005cited by this paper
• Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice.

  2005cited by this paper
• Phencyclidine-induced behaviour in mice prevented by methylene blue.

  2004cited by this paper
• Cyanide Poisoning and Its Treatment

  2004cited by this paper
• Methylene blue improves brain oxidative metabolism and memory retention in rats.

  2004cited by this paper
• Generation of oxidant stress in cultured endothelial cells by methylene blue: protective effects of glucose and ascorbic acid.

  2003cited by this paper
• Novel photochemistry of leuco-Methylene Blue.

  2003cited by this paper
• Alzheimer's disease: genes, proteins, and therapy.

  2001cited by this paper
• Oxidative Damage Is the Earliest Event in Alzheimer Disease

  2001cited by this paper
• Pharmacokinetics and organ distribution of intravenous and oral methylene blue

  2000cited by this paper
• Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease.

  2000cited by this paper
• Methylene blue inhibits hippocampal nitric oxide synthase activity in vivo.

  1999cited by this paper
• Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test.

  1999cited by this paper
• A history of antipsychotic drug development.

  1999cited by this paper
• Anxiolytic and antidepressant properties of methylene blue in animal models.

  1997cited by this paper
• The interaction between methylene blue and the cholinergic system

  1997cited by this paper
• Methylene blue adjuvant therapy of schizophrenia.

  1997cited by this paper
• Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

  1996cited by this paper
• Inhibition by sodium nitroprusside of the expression of inducible nitric oxide synthase in rat neutrophils

  1995cited by this paper
• Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.

  1994cited by this paper
• Inhibition of nitric oxide synthesis by methylene blue.

  1993cited by this paper
• Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich.

  1989cited by this paper
• A controlled trial of methylene blue in severe depressive illness.

  1987cited by this paper
• A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.

  1986cited by this paper
• Methylene blue. A possible treatment for manic depressive psychosis.

  1983cited by this paper
• Possible explanation for therapeutic action of lithium, and a possible substitute (methylene-blue)

  1981cited by this paper
• HEREDITARY DIAPHORASE DEFICIENCY AND METHEMOGLOBINEMIA.

  1964cited by this paper

• Determining susceptibility of routine clinical biochemistry assays to methylene blue interference.

  2025cites this paper
• Cardiac Arrest and Neuroprotection by Methylene Blue

  2021cites this paper
• The single intravenous administration of methylene blue after traumatic brain injury diminishes neurological deficit, blood-brain barrier disruption and decrease in the expression of S100 protein in rats.

  2020cites this paper